Prograf marks the first launch for Astellas's Indian subsidiary
This article was originally published in Scrip
Executive Summary
Astellas has launched its global mainstay product, the immunosuppressant Prograf (tacrolimus), in India, marking a step forward for the Japanese company in this major developing market.